Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin C in Allogeneic Stem Cell Transplant Recipients
NCT03613727Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascorbic acid in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Chronic Myeloid Leukemia (CML) and 1 more, sponsored by Virginia Commonwealth University. Primary endpoint: Non-relapse Mortality at 1 year. Started Oct 2018; status: completed.
02
Drugs
ascorbic acid
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)Chronic Myeloid Leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03613727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613727.